Publication at First Faculty of Medicine |
2010
Abstract
Denosumab is a fully human monoclonal antibody (lgG2) that inhibits osteoclastic-mediated bone resorption by binding to RANKL and preventing activation of the RANK receptor on osteoclasts and their precursors. Oenosumab has rapid onset and offset effects.
Oenosumab (60 mg subcutaneously every 6 months) significantly reduced vertebral, nonvertebral, and hip fracture risk compared with placebo, and had an excellent safety profile through 3 years of use.